ShanghaiJune 3, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has been recognized for the second consecutive year on the CDP “Supplier Engagement Assessment” (SEA) A List by the global environmental non-profit organization CDP. This honor highlights the company’s outstanding performance in supply chain climate change governance strategy, target setting, Scope 3 carbon emissions data disclosure, and value chain collaborative engagement. This recognition follows the company’s exceptional sustainability performance in being named to the CDP “A List” for both Climate Change and Water Security.
The CDP SEA A List aims to recognize outstanding companies that demonstrate leadership in supply chain climate action and make significant contributions to driving the transition to a net-zero sustainable economy. In 2025, over 23,000 entities (including companies, cities, regions, etc.) globally participated in CDP ratings and disclosed environmental data.
WuXi Biologics continues to strengthen its supply chain climate management capabilities, collaborating systematically with suppliers through mechanisms covering risk assessment, audits, training, and incentives. This advances Scope 3 carbon emissions data management and target tracking, drives overall value chain performance improvement, and continuously enhances supplier engagement capabilities.
WuXi Biologics has developed a comprehensive strategy to address climate change, a scientifically quantifiable target matrix, and a clear roadmap. In 2025, the company received certification from the Science Based Targets initiative (SBTi), committing to achieving net-zero emissions across its entire value chain by 2050.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of the ESG Committee, stated: “We are very honored to be named to the CDP Supplier Engagement Assessment A List for the second consecutive year. This achievement reflects the company’s ongoing efforts to strengthen supplier collaboration and enhance the sustainability performance of the value chain. As a global leader in green biopharmaceutical solutions, we will continue to work with all partners to jointly promote long-term sustainable development.”
In recent years, WuXi Biologics’ sustained commitment to sustainable development has been recognized by several internationally authoritative ESG rating agencies, including: MSCI ESG’s highest AAA rating; EcoVadis Platinum Medal; inclusion in the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class Emerging Markets Index; Morningstar Sustainalytics’ highest “Negligible Risk” rating and recognition as “Industry ESG Leader” and “Regional ESG Leader”; inclusion in the FTSE4Good Index Series; ISS ESG’s “Prime” rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index. These fully demonstrate the company’s outstanding performance in the field of sustainable development.
About WuXi Biologics
WuXi Biologics (Stock Code: 2269.HK) is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO). Through its open-access, integrated biologics capability and technology enablement platform, the company provides comprehensive end-to-end services to help partners discover, develop, and manufacture biologics, enabling the entire process from concept to commercial manufacturing. This accelerates the global biologics R&D process, reduces R&D costs, and benefits patients worldwide*.
Leveraging its global network connecting China, the United States, Ireland, Germany, and Singapore, WuXi Biologics brings together over 13,000 employees, including industry experts and scientists in biologics R&D and manufacturing, technological innovation, and operational excellence. With its leading technology platforms and deep expertise, the company provides efficient, cost-effective, and scalable biologics solutions that precisely meet customer needs at different stages. Furthermore, the company systematically integrates digital capabilities and infrastructure into the entire value chain of biologics R&D, laboratory operations, and manufacturing, transforming data, computation, and predictive capabilities into a more transparent customer collaboration experience, faster R&D processes, smarter operational management, and more efficient production delivery. As of the end of April 2026, WuXi Biologics was supporting 982 integrated projects for its clients, including 78 Phase III clinical projects and 25 commercial manufacturing projects, with complex molecule projects accounting for over 50% of the company’s total project portfolio.
WuXi Biologics regards sustainable development as the cornerstone of its long-term business growth. The company continuously promotes green innovative technologies, providing global partners with advanced end-to-end green CRDMO solutions, while continuously achieving excellence in ESG. Adhering to the concept of creating shared value, the company collaborates with stakeholders to build a sustainable ecosystem, driving both social value and ecological benefits through responsible operational models, achieving synergistic empowerment across the entire value chain.
For more information, please visit: www.wuxibiologics.com
*Awarded “2026 Biologics CDMO Leader of the Year” (Large CDMO Category)
*Awarded “2026 Best Contract Development and Manufacturing Organization” (ABEA)
For more information, please contact